Eli Lilly and Company held its third-quarter 2025 earnings conference call with the investment community on October 29, 2025. The call took place ahead of the official release of the company's financial results, which are scheduled to be announced before the market opens on Thursday, October 30th. Analysts and investors are closely watching for updates on the performance of key growth drivers, particularly the type 2 diabetes drug Mounjaro and obesity treatment Zepbound. Wall Street consensus anticipates strong year-over-year growth, with average revenue estimates around $16 billion for the quarter. The full financial results and management's commentary on the 30th will provide a clearer picture of the company's performance and outlook.